Trial Outcomes & Findings for Trial of Exercise to Reduce Cancer Related Fatigue in Breast Cancer (NCT NCT02846389)

NCT ID: NCT02846389

Last Updated: 2025-07-23

Results Overview

The Functional Assessment of Chronic Illness Therapy (FACIT) is a 13-item subscale developed to identify a finite set of concerns specific to fatigue. The responses to the 13 items on the FACIT-Fatigue questionnaire are each measured on a 4-point likert scale, with score ranging from 0 to 52 (52 being the total score allowed). The FACIT-Fatigue scale has been validated in patients with cancer and showed excellent internal consistency and reliability. Responses to questions are scored: Not at all (0), A little bit (1), Somewhat (2) Quite a bit (3), Very much (4). Some scores are reversed depending on the question. The sum of the item scores are multiplied by the number of items in the scale, then divide by the number of items answered. This produces the score. The higher the score, the better the QOL.

Recruitment status

TERMINATED

Study phase

NA

Target enrollment

24 participants

Primary outcome timeframe

Baseline, 4 weeks into RT

Results posted on

2025-07-23

Participant Flow

Participant milestones

Participant milestones
Measure
Moderate Exercise
Moderate exercise - 15 minutes a day using a pedal box before or after radiation at the hospital (75 minutes a week). Moderate Exercise: Aerobic training utilizing the portable stationary pedal exerciser (Pedlar) which contains two cycling pedals mounted to a stationary block that allows patients to exercise while sitting. Participants are required to perform 15 minutes/day of aerobic exercise using the Pedlar device on radiation treatment days; during a standard radiation course, this will typically yield 75 minutes/week of aerobic time.
Control Group
No exercise
Overall Study
STARTED
11
13
Overall Study
COMPLETED
10
12
Overall Study
NOT COMPLETED
1
1

Reasons for withdrawal

Reasons for withdrawal
Measure
Moderate Exercise
Moderate exercise - 15 minutes a day using a pedal box before or after radiation at the hospital (75 minutes a week). Moderate Exercise: Aerobic training utilizing the portable stationary pedal exerciser (Pedlar) which contains two cycling pedals mounted to a stationary block that allows patients to exercise while sitting. Participants are required to perform 15 minutes/day of aerobic exercise using the Pedlar device on radiation treatment days; during a standard radiation course, this will typically yield 75 minutes/week of aerobic time.
Control Group
No exercise
Overall Study
Withdrawal by Subject
1
1

Baseline Characteristics

Trial of Exercise to Reduce Cancer Related Fatigue in Breast Cancer

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Moderate Exercise
n=11 Participants
Moderate exercise - 15 minutes a day using a pedal box before or after radiation at the hospital (75 minutes a week). Moderate Exercise: Aerobic training utilizing the portable stationary pedal exerciser (Pedlar) which contains two cycling pedals mounted to a stationary block that allows patients to exercise while sitting. Participants are required to perform 15 minutes/day of aerobic exercise using the Pedlar device on radiation treatment days; during a standard radiation course, this will typically yield 75 minutes/week of aerobic time.
Control Group
n=13 Participants
No exercise
Total
n=24 Participants
Total of all reporting groups
Age, Categorical
<=18 years
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
10 Participants
n=5 Participants
10 Participants
n=7 Participants
20 Participants
n=5 Participants
Age, Categorical
>=65 years
1 Participants
n=5 Participants
3 Participants
n=7 Participants
4 Participants
n=5 Participants
Age, Continuous
54 years
n=5 Participants
51 years
n=7 Participants
53.5 years
n=5 Participants
Sex: Female, Male
Female
11 Participants
n=5 Participants
13 Participants
n=7 Participants
24 Participants
n=5 Participants
Sex: Female, Male
Male
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
1 Participants
n=5 Participants
5 Participants
n=7 Participants
6 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
9 Participants
n=5 Participants
8 Participants
n=7 Participants
17 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
1 Participants
n=5 Participants
0 Participants
n=7 Participants
1 Participants
n=5 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Asian
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Black or African American
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
White
11 Participants
n=5 Participants
12 Participants
n=7 Participants
23 Participants
n=5 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
1 Participants
n=7 Participants
1 Participants
n=5 Participants
Region of Enrollment
United States
11 Participants
n=5 Participants
13 Participants
n=7 Participants
24 Participants
n=5 Participants

PRIMARY outcome

Timeframe: Baseline, 4 weeks into RT

The Functional Assessment of Chronic Illness Therapy (FACIT) is a 13-item subscale developed to identify a finite set of concerns specific to fatigue. The responses to the 13 items on the FACIT-Fatigue questionnaire are each measured on a 4-point likert scale, with score ranging from 0 to 52 (52 being the total score allowed). The FACIT-Fatigue scale has been validated in patients with cancer and showed excellent internal consistency and reliability. Responses to questions are scored: Not at all (0), A little bit (1), Somewhat (2) Quite a bit (3), Very much (4). Some scores are reversed depending on the question. The sum of the item scores are multiplied by the number of items in the scale, then divide by the number of items answered. This produces the score. The higher the score, the better the QOL.

Outcome measures

Outcome measures
Measure
Moderate Exercise
n=11 Participants
Moderate exercise - 15 minutes a day using a pedal box before or after radiation at the hospital (75 minutes a week). Moderate Exercise: Aerobic training utilizing the portable stationary pedal exerciser (Pedlar) which contains two cycling pedals mounted to a stationary block that allows patients to exercise while sitting. Participants are required to perform 15 minutes/day of aerobic exercise using the Pedlar device on radiation treatment days; during a standard radiation course, this will typically yield 75 minutes/week of aerobic time.
Control Group
n=13 Participants
No exercise
Assessment of Change in Fatigue Via Functional Assessment of Chronic Illness Therapy (FACIT-Fatigue) Survey Instrument.
Baseline
17 FACIT Score
Standard Deviation 11
14 FACIT Score
Standard Deviation 8
Assessment of Change in Fatigue Via Functional Assessment of Chronic Illness Therapy (FACIT-Fatigue) Survey Instrument.
4 weeks into RT
21 FACIT Score
Standard Deviation 9
18 FACIT Score
Standard Deviation 14

PRIMARY outcome

Timeframe: Baseline, 4 weeks into RT

Serum hsCRP will be measured on the Vitros 5,1 FS Chemistry platform via an immunoassay with a reportable range of 0.10 -15.00 mg/L, and intra- and inter-assay CVs of 1.8-4.0%. Change is reported based on the difference in the group mean of Serum hsCRP level between baseline and T4 visit.

Outcome measures

Outcome measures
Measure
Moderate Exercise
n=11 Participants
Moderate exercise - 15 minutes a day using a pedal box before or after radiation at the hospital (75 minutes a week). Moderate Exercise: Aerobic training utilizing the portable stationary pedal exerciser (Pedlar) which contains two cycling pedals mounted to a stationary block that allows patients to exercise while sitting. Participants are required to perform 15 minutes/day of aerobic exercise using the Pedlar device on radiation treatment days; during a standard radiation course, this will typically yield 75 minutes/week of aerobic time.
Control Group
n=13 Participants
No exercise
Assessment of Change in Blood Biomarker of Inflammation: High Sensitivity CRP (hsCRP)
Baseline
0.39 milligrams per liter (mg/L)
Standard Deviation 0.47
0.29 milligrams per liter (mg/L)
Standard Deviation 0.33
Assessment of Change in Blood Biomarker of Inflammation: High Sensitivity CRP (hsCRP)
4 weeks into RT
0.21 milligrams per liter (mg/L)
Standard Deviation 0.19
0.13 milligrams per liter (mg/L)
Standard Deviation 0.14

PRIMARY outcome

Timeframe: Baseline, 4 weeks into RT

Fibrinogen will be measured using standardized clinical protocols. All assays have intra- and inter-assays coefficient of variations \<10%. Change is reported based on the difference in the group mean of Serum fibrinogen level between baseline and T4 visit.

Outcome measures

Outcome measures
Measure
Moderate Exercise
n=11 Participants
Moderate exercise - 15 minutes a day using a pedal box before or after radiation at the hospital (75 minutes a week). Moderate Exercise: Aerobic training utilizing the portable stationary pedal exerciser (Pedlar) which contains two cycling pedals mounted to a stationary block that allows patients to exercise while sitting. Participants are required to perform 15 minutes/day of aerobic exercise using the Pedlar device on radiation treatment days; during a standard radiation course, this will typically yield 75 minutes/week of aerobic time.
Control Group
n=13 Participants
No exercise
Assessment of Change in Blood Biomarker of Inflammation: Serum Fibrinogen
Baseline
326 milligrams per deciliter (mg/dL)
Standard Deviation 69
307 milligrams per deciliter (mg/dL)
Standard Deviation 116
Assessment of Change in Blood Biomarker of Inflammation: Serum Fibrinogen
4 weeks into RT
288 milligrams per deciliter (mg/dL)
Standard Deviation 78
296 milligrams per deciliter (mg/dL)
Standard Deviation 77

PRIMARY outcome

Timeframe: Baseline, 4 weeks into RT

Ferritin will be measured using standardized clinical protocols. All assays have intra- and inter-assays coefficient of variations \<10%. Change is reported based on the difference in the group mean of ferritin levels between baseline and T4 visit.

Outcome measures

Outcome measures
Measure
Moderate Exercise
n=11 Participants
Moderate exercise - 15 minutes a day using a pedal box before or after radiation at the hospital (75 minutes a week). Moderate Exercise: Aerobic training utilizing the portable stationary pedal exerciser (Pedlar) which contains two cycling pedals mounted to a stationary block that allows patients to exercise while sitting. Participants are required to perform 15 minutes/day of aerobic exercise using the Pedlar device on radiation treatment days; during a standard radiation course, this will typically yield 75 minutes/week of aerobic time.
Control Group
n=13 Participants
No exercise
Assessment of Change in Blood Biomarker of Inflammation: Ferritin
Baseline
0.009 Micrograms per liter (mcg/L)
Standard Deviation 0.005
0.005 Micrograms per liter (mcg/L)
Standard Deviation 0.006
Assessment of Change in Blood Biomarker of Inflammation: Ferritin
4 weeks into RT
0.008 Micrograms per liter (mcg/L)
Standard Deviation 0.003
0.006 Micrograms per liter (mcg/L)
Standard Deviation 0.004

SECONDARY outcome

Timeframe: Baseline, 4 weeks into RT

The Health-related quality of life (HRQOL) measures four different domains (physical well-being, functional well-being, emotional well-being, and social/family well-being). Functional Assessment of Cancer Therapy (FACT-B) is a breast cancer specific module that will be used to reflect patients' concerns; moreover, they are reliable, reproducible, and have been validated in numerous studies. Score ranging from 0 to 148 (148 being the total score allowed). Responses to questions are scored: Not at all (0), A little bit (1), Somewhat (2) Quite a bit (3), Very much (4). Some scores are reveresed depending on the question. The sum of the item scores are multiplied by the number of items in the scale, then divide by the number of items answered. This produces the score. The higher the score, the better the QOL. Change in the group sum of the FACT score between baseline and T4 visit.

Outcome measures

Outcome measures
Measure
Moderate Exercise
n=11 Participants
Moderate exercise - 15 minutes a day using a pedal box before or after radiation at the hospital (75 minutes a week). Moderate Exercise: Aerobic training utilizing the portable stationary pedal exerciser (Pedlar) which contains two cycling pedals mounted to a stationary block that allows patients to exercise while sitting. Participants are required to perform 15 minutes/day of aerobic exercise using the Pedlar device on radiation treatment days; during a standard radiation course, this will typically yield 75 minutes/week of aerobic time.
Control Group
n=13 Participants
No exercise
Assessment of Change in Cancer-related Healthcare Quality of Life (HRQOL) Measured Using the Functional Assessment of Cancer Therapy (FACT) System Questionnaires.
Baseline
70 units on a scale
Standard Deviation 8
69 units on a scale
Standard Deviation 8
Assessment of Change in Cancer-related Healthcare Quality of Life (HRQOL) Measured Using the Functional Assessment of Cancer Therapy (FACT) System Questionnaires.
4 weeks into RT
66 units on a scale
Standard Deviation 11
71 units on a scale
Standard Deviation 10

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline, 4 weeks into RT, 4 week follow up visit

We will collect CBC data at each blood draw for correlative and explorative purposes.

Outcome measures

Outcome data not reported

Adverse Events

Moderate Exercise

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Control Group

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Joshua Zenreich

Hackensack Meridian Health

Phone: 15519964248

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place